Anticoagulation

Two patients, both newly diagnosed with atrial fibrillation in the same week. One is a straightforward guideline case. For the other, a single medication already on the chart changes the entire calculus.

A single patient, three weeks from an elective knee replacement, on lifelong warfarin for a mechanical mitral valve. The disagreement isn't about whether to bridge her anticoagulation — that much is settled — it's about which drug does the bridging, now that impaired renal clearance takes the usual first choice off the table.

A single patient, seven weeks out from a proximal DVT, three weeks from a knee replacement she's counted down to for months. The disagreement isn't about which bridging drug to use — it's about whether the trial everyone is citing ever actually studied someone in her position.

A patient stable on apixaban for atrial fibrillation is diagnosed with colon cancer requiring surgery within weeks. Holding the drug before the operation isn't in question — that part is routine. What's newly uncertain is whether the interruption should look anything like it would have a month ago, before a new cancer diagnosis added its own pull on the same decision.

A single patient, eighty years old, whose weight and creatinine each miss apixaban's dose-reduction cutoffs by a narrow margin — and whose calculated creatinine clearance points to a very different picture than her lab-reported creatinine does on its own.

A 34-year-old veterinary technician, fourteen months past an ischemic stroke and confirmed triple-positive for antiphospholipid antibodies, wants to trade her warfarin and regular blood draws for a once-daily anticoagulant. The evidence on that trade is specific to her exact antibody profile — and unusually clear. What isn't yet resolved is how to make her ongoing monitoring less of a burden.

A new diagnosis of atrial fibrillation in a patient whose body mass index exceeds 50 raises a real anticoagulation question: apixaban has reassuring trial data even at high body weight, but the two most detailed specialty guidance documents disagree on exactly where added caution should begin, and neither was calibrated to a patient exactly this size.

Six months of full-dose apixaban completed for a first unprovoked PE, no persistent risk factor found, and a moderate bleeding-risk profile from years of NSAID use. Three real options sit on the table, and one of them turns out to rest on evidence that doesn't hold up.

A remote heparin-induced thrombocytopenia history and a brand-new reason to need long-term anticoagulation. The complication isn't which drug treats her AF — it's what starting each option actually requires from a patient who can never touch heparin again.

Months of erratic INR control on a mechanical valve that leaves no room for guesswork. The two largest trials testing whether genotyping helps reached opposite conclusions — and the difference wasn't chance, it was who was studied.

High-risk AF, a scheduled polypectomy, and an instinct — carried over from the warfarin era — to protect a high-risk patient with a bridging anticoagulant. The pharmacology of the drug he's actually on argues that instinct doesn't transfer.

Both drugs' labels say the same thing at the boundary he's approaching: avoid beyond this point. The actual exposure data behind that shared warning tells two different stories about which drug gets there faster.

For years, advanced liver disease was treated as its own kind of blood thinner, a condition that made real anticoagulation seem redundant. Current evidence says his atrial fibrillation doesn't care what his liver is doing, and neither does his stroke risk.

Guidelines still point to warfarin for this exact finding, resting on decades of accumulated practice rather than a controlled trial. Multiple newer trials, including the largest one to date, found something the guideline text hasn't yet absorbed.

A single patient whose device implant is routine and whose anticoagulation history is not, which turns a standard pre-procedure checklist into a genuine judgment call.

A single patient whose emergency surgery is straightforward and whose anticoagulation is not, because the valve keeping her alive can't simply be left unprotected for the sake of a cleaner operating field.